FDA approve libido enhancing drug for women with low sexual desire
pharmafile | June 24, 2019 | News story | Sales and Marketing | FDA, HSDD, health, pharma, viagra, vyleesi
The FDA has approved a new drug for women with low libido.
The FDA has approved AMAG Pharmaceuticals’ bremelanotide – sold under the brand name Vyleesi – for premenopausal women with generalised hypoactive sexual desire disorder (HSDD), in which a lack of interest in sex may cause significant distress in a woman’s life.
Vyleesi, produced by Waltham, Massachusetts-based firm AMAG, will be available in September, the company said. AMAG have not yet decided on a price tag for the libido increasing drug.
HSDD is thought to have a neurological basis. Brain imaging studies show differences in activation patterns between women with and without HSDD.
“Most women who come into my office have no idea that there’s this condition … and that they are one of millions,” said Sheryl Kingsberg, division chief of Behavioral Medicine at University Hospitals Cleveland Medical Center.
“The impact of sexual dysfunction on a woman’s self-esteem, on her body image, on her self-confidence and on her relationship is profound,” Kingsberg said.
While Vyleesi has been dubbed the ‘female Viagra,’ the melanocortin receptor agonist actually works on receptors in the brain to increase sexual desire. The injectable drug is self-administered using an auto injector.
“Women with HSDD often avoid situations that could lead to intimacy, the impact of which goes far beyond the bedroom and can often result in anxiety, loss of vitality, self-esteem issues and relationship stress. It is important that women suffering with this condition have a choice of treatment options available to them.”
Louis Goss
Related Content
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …
